A5044421583- Hepatitis C virus research
- Virus-based gene therapy research
- Hepatitis B Virus Studies
- Immunotherapy and Immune Responses
- T-cell and B-cell Immunology
- vaccines and immunoinformatics approaches
- SARS-CoV-2 and COVID-19 Research
- Immune Cell Function and Interaction
- Viral gastroenteritis research and epidemiology
- HIV Research and Treatment
- Respiratory viral infections research
- Chemical Synthesis and Analysis
- Monoclonal and Polyclonal Antibodies Research
- Colonialism, slavery, and trade
- CAR-T cell therapy research
- Cytomegalovirus and herpesvirus research
- Virology and Viral Diseases
- Anthropological Studies and Insights
- Religion and Society in Latin America
- Multiculturalism, Politics, Migration, Gender
- Carbohydrate Chemistry and Synthesis
- Viral Infections and Outbreaks Research
- African Studies and Geopolitics
- Hepatitis Viruses Studies and Epidemiology
- Caribbean and African Literature and Culture
Centre d’études en sciences sociales du religieux
2018-2024
Carilion Clinic
2023
Virginia Tech
2023
Azienda Sanitaria Locale Roma 3
2023
Secretaria Regional do Ambiente e Recursos Naturais
2018-2021
Centre National de la Recherche Scientifique
2021
École des hautes études en sciences sociales
2020
ETH Zurich
2007-2015
Novartis (Switzerland)
2011-2015
Astronomical Observatory of Capodimonte
2008-2014
Currently, no vaccine exists for hepatitis C virus (HCV), a major pathogen thought to infect 170 million people globally. Many studies suggest that host T cell responses are critical spontaneous resolution of disease, and preclinical have indicated requirement cells in protection against challenge. We aimed elicit HCV-specific with the potential using recombinant adenoviral vector strategy phase 1 study healthy human volunteers. Two vectors expressing NS proteins from HCV genotype 1B were...
A prime-boost HCV vaccine strategy induces durable and broad T cell responses, characteristic of those associated with viral control.
Simian adenoviruses screened from wild-derived candidates can prime T cell responses in man and may serve as new vaccine vector candidates.
A safe and effective vaccine to prevent chronic hepatitis C virus (HCV) infection is a critical component of efforts eliminate the disease.
Mucosal-associated invariant T (MAIT) cells are innate sensors of viruses and can augment early immune responses contribute to protection. We hypothesized that MAIT may have inherent adjuvant activity in vaccine platforms use replication-incompetent adenovirus vectors. In mice humans, ChAdOx1 (chimpanzee Ox1) immunization robustly activated cells. Activation required plasmacytoid dendritic cell (pDC)-derived interferon (IFN)-α monocyte-derived interleukin-18. IFN-α-induced, tumor necrosis...
β-Amino acids with a single side chain in the α-position (β²-amino or H-β²hXaa(PG)-OH; i.e., homo-amino proteinogenic chains) have turned out to be important components β-peptides. They contribute unique secondary structures, they are required for mimicking structure and activity of β-turn-forming α-peptides, can used protecting α-peptides against attack by aminopeptidases. In contrast β³-homo-amino acids, β²-isomers cannot obtained simply enantiospecific homologation (natural) α-amino but...
Early, vigorous intrahepatic induction of interferon (IFN)-stimulated gene (ISG) is a feature hepatitis C virus (HCV) infection, even though HCV inhibits the type I IFNs in vitro. To identify cytokines and cells that drive ISG mediate antiviral activity during acute III IFN responses were studied (1) serial liver biopsies plasma samples obtained from 6 chimpanzees throughout infection (2) primary human hepatocyte (PHH) cultures upon infection. Type minimally induced at messenger RNA (mRNA)...
The RSV vaccine candidates PanAd3-RSV and MVA-RSV were safe immunogenic in healthy adults.
The 2014 West African outbreak of Ebola virus disease highlighted the urgent need to develop an effective vaccine. We undertook 2 phase 1 studies assessing safety and immunogenicity viral vector modified vaccinia Ankara vectored Zaire vaccine (MVA-EBO-Z), manufactured rapidly on a new duck cell line either alone or in heterologous prime-boost regimen with recombinant chimpanzee adenovirus type 3 (ChAd3-EBO-Z) followed by MVA-EBO-Z. Adult volunteers United Kingdom (n = 38) Senegal 40) were...
Trial Design HIV-1 vaccine development has advanced slowly due to viral antigenic diversity, poor immunogenicity and recently, safety concerns associated with human adenovirus serotype-5 vectors. To tackle variation, we designed a unique T-cell immunogen HIVconsv from functionally conserved regions of the proteome, which were presented immune system using heterologous prime-boost combination plasmid DNA, non-replicating simian (chimpanzee) ChAdV-63 poxvirus, modified vaccinia virus Ankara. A...
Human respiratory syncytial virus (HRSV) is a major cause of lower tract disease in children and the elderly for which there still no effective vaccine. We have previously shown that PanAd3-RSV, chimpanzee adenovirus-vectored vaccine candidate expresses secreted form HRSV F protein together with N M2-1 proteins HRSV, immunogenic rodents nonhuman primates, protects mice cotton rats from challenge. Because extent to protection demonstrated rodent models will translate humans unclear, we...
The induction and maintenance of T cell memory is critical to the success vaccines. A recently described subset CD8+ cells defined by intermediate expression chemokine receptor CX3CR1 was shown have self-renewal, proliferative, tissue-surveillance properties relevant vaccine-induced memory. We tracked these when sustained at high levels: inflation induced cytomegalovirus (CMV) adenovirus-vectored In mice, both CMV inflationary showed levels CX3R1int exhibiting an effector-memory phenotype,...
The coronavirus disease 2019 (COVID-19) pandemic caused by the emergent severe acute respiratory syndrome 2 (SARS-CoV-2) threatens global public health, and there is an urgent need to develop safe effective vaccines. Here, we report generation preclinical evaluation of a novel replication-defective gorilla adenovirus-vectored vaccine encoding pre-fusion stabilized Spike (S) protein SARS-CoV-2. We show that our candidate, GRAd-COV2, highly immunogenic both in mice macaques, eliciting...
We describe an improved genetic immunization strategy for eliciting a full spectrum of anti-hepatitis C virus (HCV) envelope 2 (E2) glycoprotein responses in mammals through electrical gene transfer (EGT) plasmid DNA into muscle fibers. Intramuscular injection encoding cross-reactive hypervariable region 1 (HVR1) peptide mimic fused at the N terminus E2 ectodomain, followed by stimulation treatment form high-frequency, low-voltage electric pulses, induced more than 10-fold-higher expression...
Abstract The new electrophilic trifluoromethylating 1‐(trifluoromethyl)‐benziodoxole reagents A and B ( Scheme 1 ) have been used to selectively attach CF 3 groups the S‐atom of cysteine side chains α ‐ β ‐peptides (up 13‐residues‐long; products 7 – 14 ). Other functional in substrates (amino, amido, carbamate, carboxylate, hydroxy, phenyl) are not attacked by these soft reagents. Depending on conditions, indole ring a Trp residue may also be trifluoromethylated (in 2‐position). purified...
ABSTRACT Success in resolving hepatitis C virus (HCV) infection has been correlated to vigorous, multispecific, and sustained CD8 + T-cell response humans chimpanzees. The efficacy of inducing T-cell-mediated immunity by recombinant serotype 5 adenovirus vector proven many animal models infectious diseases, but its immunogenicity can be negatively influenced preexisting against the itself. To evaluate less prevalent 6 (Ad6) as an alternative for HCV vaccine development, we have generated...
Induction of multispecific, functional CD4+ and CD8+ T cells is the immunological hallmark acute self-limiting hepatitis C virus (HCV) infection in humans. In present study, we showed that gene electrotransfer (GET) a novel candidate DNA vaccine encoding an optimized version nonstructural region HCV (from NS3 to NS5B) induced substantially more potent, broad, long-lasting cellular immunity than naked injection mice rhesus macaques as measured by combination assays, including IFN-gamma...
Protein-in-adjuvant formulations and viral-vectored vaccines encoding blood-stage malaria Ags have shown efficacy in rodent models vitro assays against Plasmodium falciparum. Abs CD4(+) T cell responses are associated with protective malaria, whereas CD8(+) cells some classical can also a effect liver-stage parasites. No subunit vaccine strategy alone has generated demonstrable high-level infection clinical trials. The induction of Ab responses, as well potent B effector memory populations,...
Memory CD8+ T cells generated by spontaneous resolution of hepatitis C virus (HCV) infection rapidly control secondary infections and reduce the risk persistence. Here, T-cell immunity response to reinfection were assessed in a chimpanzee cured an earlier chronic with interferon (IFN)-free antiviral regimen. expanded from liver immediately before 2 years after cure two direct-acting antivirals (DAAs) targeted epitopes E2, nonstructural (NS)5a, NS5b proteins. A second assess responsiveness...
Respiratory syncytial virus (RSV) infection causes respiratory disease throughout life, with infants and the elderly at risk of severe death. RSV001 is a phase 1 (first-in-man), open-label, dose-escalation, clinical trial novel genetic viral-vectored vaccine candidates PanAd3-RSV modified vaccinia Ankara (MVA)-RSV. The objective to characterise (primary objective) safety (secondary immunogenicity these vaccines in healthy younger older adults.